PCRX241220C42500
- 0.75
- 0.000.00%
Pacira BioSciences Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis With Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation
Express News | Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201
Express News | Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported
Express News | Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences Insider Lowered Holding By 85% During Last Year
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences Price Target Cut to $17.00/Share From $25.00 by Barclays
Pacira BioSciences Is Maintained at Equal-Weight by Barclays
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $22
Pacira BioSciences Analyst Ratings
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39
Express News | Pacira Biosciences Inc : Piper Sandler Raises Target Price to $12 From $11
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript Summary
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira BioSciences | 10-Q: Q3 2024 Earnings Report